Christopher Bourne, BA

Cancer immunotherapy has shown remarkable results in subsets of cancers. However, further optimization is required to broaden and enhance the efficacy of immunotherapy in all cancers. I aim to use adoptive T cell therapeutics to deliver small molecule drugs at tumor sites. I engineer CAR T cells and tumor-specific TCR T cells to deliver enzymes to tumors that are capable of unmasking prodrugs. This work uncovers the mechanisms behind T cell trafficking to tumors.
 

Social Media, Twitter: @TheBourneImmuno, @BlackinCancer